ACR25 Best Abstracts - Day 4

Jack Cush, MD

Oct 31, 2025 3:52 pm

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest pic.twitter.com/Sq7m9sXlLP
— Md Yuzaiful Md Yusof (@Yuz6Yusof) October 29, 2025

McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest pic.twitter.com/ghHEKztvgz
— Richard Conway (@RichardPAConway) October 29, 2025

Konsta et al. Adding NSAID to TNF inhibits spinal but not hip radiograpic progress. 262 patients, TNF+NSAID 100, TNF alone 162. New syndesmophytes 36% vs 58%. ΔmSASSS-score/year 0.1 vs 0.7. No effect on progression of hip radiographs. @RheumNow #ACR25 Abstr#2359 #ACRBest pic.twitter.com/k9j2M2E3ze
— Richard Conway (@RichardPAConway) October 28, 2025

#PD1 Ab looks good and safe in active RA

Rosnilimab, a Selective and Potent Depleter of Pathogenic T

Many failed several Rx already
No safety signals compared to another PD1i

Proof of benefit in biospecimens too!

abst#LB19 #ACR25 @RheumNow @ACRheum #ACRBest pic.twitter.com/TmEOCfuHZU
— Janet Pope (@Janetbirdope) October 29, 2025

HCQ weight-based dosing: out
HCQ whole blood monitoring: in

Whole blood levels more precisely balance risks of SLE flare (under-dosing) vs. toxicitiy (over-dosing)

Many pt on <5 mg/kg had supra-therapeutic blood levels with risk for toxicity@RheumNow #ACR25 #ACRBest Abst 1722 pic.twitter.com/qIbACxAW39
— Brian Jaros, MD (@Dr_Brian_MD) October 28, 2025

#ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest pic.twitter.com/MecTYMpH0o
— Md Yuzaiful Md Yusof (@Yuz6Yusof) October 29, 2025

CAR T
Which cells to target
What patients & what disease
When is right time
In vivo (new) ex vivo
Premeds immune suppression
What to use, ?if anything
Cons
Is it safe
?long term effectiveness
What is failure rate
ICANs and other side effects#ACRBest #ACR25 @RheumNow #26S21 https://t.co/JiqYzgBmYP pic.twitter.com/TUSJh1hrPr
— Janet Pope (@Janetbirdope) October 30, 2025

Girolami et al. VA study. Safety of DMARDs in RA following melanoma. 644 patients. 3 year all cause mortality. No significant difference, but graph sure looks like b/tsDMARDs are better. No melanoma specific mortality/recurrence data however. @RheumNow #ACR25 Abstr#2237 #ACRBest pic.twitter.com/IN4LDkioT7
— Richard Conway (@RichardPAConway) October 28, 2025